|
Thu, 07/24/2025 - 04:14 |
Chugai to Construct a New Laboratory Building UKX to Strengthen Manufacturing Process Development Capabilities and Advance Environmental Initiatives toward TOP I 2030 |
Chugai |
|
Fri, 01/17/2025 - 05:27 |
Chugai Wins the MHLW Ministers Award at the Seventh Japan Medical Research and Development Grand Prize for the Discovery of an ALK-Positive Lung Cancer Treatment Alecensa |
Chugai |
|
Mon, 12/16/2024 - 13:39 |
Personalized cancer treatment The Launch of Chugais New TV Commercial Featuring Tori Matsuzaka Innovation Lab / Cancer Genomic Medicine |
Chugai |
|
Wed, 08/28/2024 - 05:10 |
Transfer and Future Marketing of Secondary Hyperparathyroidism Drug OXAROL for Injection in Japan |
Chugai |
|
Fri, 08/09/2024 - 08:21 |
Chugai Continues to be Listed for All ESG Indices Adopted by GPIF |
Chugai |
|
Wed, 08/07/2024 - 07:51 |
Chugai In-Licenses Anti-TL1A Antibody RG6631 for the Intractable Diseases Ulcerative Colitis and Crohns Disease |
Chugai |
|
Fri, 08/02/2024 - 16:21 |
Chugais Alecensa Approved in Taiwan as an Adjuvant Treatment for Early Stage ALK-Positive Non-Small Cell Lung Cancer (NSCLC) |
Chugai |
|
Mon, 07/22/2024 - 15:45 |
Transfer and Future Marketing of Physiological Intestinal Function Improving and Hyperammonemia Drug MONILAC Syrup 65% in Japan |
Chugai |
|
Thu, 02/08/2024 - 23:01 |
Crovalimab Approved in China as the First Country, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Chugai |
|
Fri, 02/02/2024 - 02:03 |
Chugai Announces 2023 Full Year Results and Forecasts for 2024 |
Chugai |
|
Thu, 01/31/2019 - 04:20 |
Record-high revenues and Core operating profit for two consecutive years at 579.8 billion and 130.3 billion, respectively |
Chugai |
|
Thu, 01/10/2019 - 16:58 |
Mid-career Recruitment Job Openings and Recruitment Information |
Chugai |
|
Wed, 12/19/2018 - 10:40 |
Overview of Chugais Research Activities Chugais Seven Strengths |
Chugai |
|
Mon, 12/10/2018 - 07:30 |
Establishment of " Gan with," an Information Website for Cancer Patients, Their Families and Coworkers |
Chugai |
|
Wed, 12/05/2018 - 08:14 |
Chugai Files Lawsuit against Alexion for Infringement of its Proprietary Antibody Engineering Technology in Japan |
Chugai |
|
Mon, 12/03/2018 - 11:50 |
Roches Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors |
Rocheusa |
|
Sun, 12/02/2018 - 20:46 |
Genentechs Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors |
Genentech |
|
Thu, 11/15/2018 - 22:40 |
Chugai Files Lawsuit against Alexion for Infringement of its Proprietary Antibody Engineering Technology in the U.S. |
Chugai |
|
Thu, 10/18/2018 - 17:53 |
Guidelines on Relation with Medical Institutions and Patient Groups |
Chugai |
|
Mon, 10/15/2018 - 15:05 |
Message from the Deputy Chairman of the Board |
Chugai |
|
Mon, 10/15/2018 - 14:42 |
Chugai Expresses its Support for the Japan Climate Action Summit Declaration |
Chugai |
|
Fri, 10/12/2018 - 10:12 |
Filing of Lawsuit on Patent Infringement Concerning Herceptin Injection, and a Petition for Provisional Disposition Order (1) |
Chugai |
|
Fri, 10/12/2018 - 09:23 |
Filing of Lawsuit on Patent Infringement Concerning Herceptin Injection, and a Petition for Provisional Disposition Order (2) |
Chugai |
|
Fri, 10/12/2018 - 09:19 |
Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists |
Chugai |
|
Wed, 10/03/2018 - 22:34 |
FDA approves Roches Hemlibra for haemophilia A without factor VIII inhibitors |
Rocheusa |
